Royalty Report: Drugs, Delivery, Disease – Collection: 338651


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Delivery
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 338651

License Grant
Licensor of Ireland grants the Licensee, also of Ireland, an exclusive, sublicensable license, solely in the field in the territory to use the Licensor technology, including intellectual property rights to sell and market and exploit the regulatory filings for the products in the field in the territory
License Property
LiquiTime® is a drug delivery platform for modified, extended and controlled release of liquid oral drugs.

Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.

The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).

Field of Use
Licensee has licensed rights to the LiquiTime® drug delivery platform for the U.S. Over-the-Counter (OTC) drug market.

The exclusive license includes Licensor’s LiquiTime® Ibuprofen and LiquiTime® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant.  These are the initial products.

IPSCIO Record ID: 319177

License Grant
Licensor grants an exclusive license to its Intellectual Property only to the extent necessary to research, develop, make, have made, offer for sale, sell Products in the United States and its territories.
License Property
Licensor has developed the following extended-release liquid Products to be sold by doctors prescription only containing the following active pharmaceutical ingredients in accordance with the terms hereof using Neos patent-pending Dynamic Time Release Suspension technology.  Products include Chlorpheniramine and Hydrocodone; Promethazine with Hydrocodone; Fexofenadine with Pseudoephedrine combination product; and Guaifenesin with Hydrocodone or Codeine.

Licensor has developed a broad, proprietary modified-release drug delivery technology that enables the manufacture of single and multiple ingredient extended-release (XR) pharmaceuticals in patient- and caregiver-friendly orally disintegrating tablet (ODT) and oral suspension dosage forms.

Field of Use
The field of use is pharmaceutical products in the form of an extended release liquid.

Licensee is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets.

IPSCIO Record ID: 243442

License Grant
Assignor sells, transfers, assigns and delivers to Assignee all of Assignors right, title and interest in and to the Patent Application and the Intellectual Property.
License Property
The Licensors technology is known as oral extended release dosage form based on the principle of controlled hydration.

The CDT system is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. We believe we can apply our technology to create significant enhancements to existing pharmaceutical, OTC and nutraceutical products.

Proprietary CDT technology improves upon conventional multiple daily dose immediate release forms of existing products by providing the therapeutic benefits of controlled release drug delivery. In addition, we believe our technology can provide enhanced dosage formats for existing medications that provide superior patient convenience and product differentiation.

Field of Use
The use is for oral extended release dosage.

The technology has allowed Assignor cost-effectively develop formulations for the OTC and nutritional industries, such as  glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, Novasoy®, and other difficult compounds and branded ingredients.

IPSCIO Record ID: 368511

License Grant
Licensor grants an exclusive license throughout the Territory, with the right to grant sublicenses, under the Licensor Technology, to conduct the Development and Regulatory Program and the Commercialization Program, with respect to the Products including Licensor Technology which may result from the Development and Regulatory Program and to use, market, sell, have sold and distribute such Product in the Territory; provided, however, that nothing shall alter the rights of Licensor contained in this Agreement to manufacture the Product.
License Property
Initial Platform Technology, with respect to the Initial Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783, 181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvement thereto whether patentable or not.

Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.

Compound shall mean morphine sulfate and/or morphine polystyrene.

Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIAN® Referenced Product

KADIAN® NT shall mean the abuse deterrent form of the KADIAN® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.

Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIAN® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIAN® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.

Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.

Field of Use
The field of use for KADIAN is as an extended release morphine sulfate pain medication.

Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIAN® solid dose product line.

IPSCIO Record ID: 236350

License Grant
The Licensor will develop and provide the Company with four stable product formulations utilizing its proprietary LiquiTime® and Micropump® technology. Upon transfer of the product formulations, the Company will assume all remaining development and regulatory costs.
License Property
The LiquiTime® and Micropump® technology are prescription drugs that treat a range of pediatric diseases, disorders and conditions.
Field of Use
This agreement pertains to the drug industry relating to pediatric healthcare.

IPSCIO Record ID: 27061

License Grant
The Company has previously agreed to pay royalties to CONSULTANT, a member of the Company's Board of Directors, in recognition of the patents developed by CONSULTANT for TIMERx.
License Property
The Company has developed the TIMERx delivery system, a novel drug delivery technology, to address the limitations of currently available oral controlled release delivery systems. The Company believes that the TIMERx system is a major advancement in oral drug delivery that represents the first easily-manufactured oral controlled release drug delivery system that is applicable to a wide variety of drug classes, including soluble drugs, insoluble drugs and drugs with a narrow therapeutic index. The Company is utilizing the TIMERx system to formulate generic versions of branded controlled release drugs, controlled release formulations of currently-marketed.

The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.

1)  Directly compressible sustained release excipient.

2)  Sustained release excipient and tablet formulation.

3)  Compressible sustained release solid dosage forms.

4)  EPO Application No. 89309518.2; filed September 19, 1989.

5)  Australian Patent Application No. 43057/89

6)  Japanese Patent Application No. 1-510135

7)  Irish Patent Application No. 2968/89

8)  Canadian Patent Application No. 611,700

9)  Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.

10)  2 U.S. Applications on Bi-modal release.

IPSCIO Record ID: 1185

License Grant
Irish Licensor grants, and Licensee accepts, upon the terms set forth in this Agreement, an Exclusive, irrevocable right and license in the Territory, under the Patents and the Know-How, to develop, market, use, distribute, import, export, offer to sell and sell (but not produce or manufacture) the Products and any Improvements thereto.

Licensee desires to acquire from Licensor, and Licensor is willing to grant to Licensee, an Exclusive (as hereinafter defined) license under Licensor’s Patents, Know-How and Trademarks relating to the Products in the Territory.

License Property
Patents means as for Product A as hereinafter defined (a) International Application WO/2000/76478, US App. No. 10/009,532 titled Controlled Release And Taste Masking Oral Pharmaceutical Compositions, US App. No. 11, 268/500 titled Controlled Release And Taste Masking Oral Pharmaceutical Compositions, and related applications thereof, including all other provisional and other patent applications including, but not limited to, US App. No 12/210,969, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including utility, model and design patents and certificates of invention, including, but not limited to, US Patent No. 7,410,651 titled Controlled release and taste masking oral pharmaceutical compositions, US Patent No. 7.431,943 titled Controlled release and taste masking oral pharmaceutical compositions.

Product A any oral formulation product containing Budesonide or other anti-inflammatory corticosteroids as an active ingredient, formulated with a multi-matrix (MMX) drug releasing technology, for the treatment of patients with Ulcerative Colitis and all other human uses.

Product B any oral formulation product containing Rifamycin SV as an active ingredient, formulated with a multi-matrix (MMX) drug releasing technology, for the treatment of patients with Travelers’ Diarrhea and all other human uses.  

Budesonide MMX is an oral corticosteroid currently being investigated in two multi-center phase III clinical trials and Rifamycin SV MMX is a broad spectrum, semi-synthetic antibiotic that also has targeted release characteristics when taken orally. MMX is a proprietary technology platform designed to produce a controlled release, homogeneous local application of the active pharmaceutical ingredient throughout the colon, thereby limiting systemic absorption and offering an opportunity for reduced side effects. The MMX technology is covered by two issued U.S. patents that expire in mid-2020, and additional patent applications are pending at the U.S. Patent and Trademark Office.

Field of Use
Licensee possesses capabilities in marketing, development and commercialization of pharmaceutical products in the Territory.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.